A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Trial Details

NCT ID
NCT07681596
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • AZD4045
  • Daratumumab
  • Aldesleukin
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Denver, Colorado, United States|39.73915,-104.9847
  • Tampa, Florida, United States|27.94752,-82.45843
  • Atlanta, Georgia, United States|33.749,-84.38798
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Participant must be 18 years or older at the time of signing the informed consent form.
  • Participants must have documented diagnosis of MM according to the IMWG diagnostic criteria.
  • Participant must have one or more of the following measurable disease criteria:
  • Serum M-protein level ≥ 1.0 g/dL.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →